GoAI
Get started
Alpha Teknova, Inc. logo

Alpha Teknova, Inc.

TKNO

NASDAQHealthcareDrug Manufacturers - Specialty & Generic

Open in GoAI

Previous close

$7.36

+$0.36 · +5.14%

Aug 21, 4:00 PM ET

TKNO company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

62

Undervalued

Momentum

68

Gaining

Sentiment

52

Mixed

Risk resilience

47

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Alpha Teknova, Inc. supplies vital scientific reagents to the life sciences sector across both the United States and international markets. These crucial materials play a key role in facilitating the exploration, evolution, and ultimate production of biopharmaceutical goods, such as advanced drug treatments, new vaccines, and molecular diagnostic solutions. The company's product offerings encompass pre-filled media plates designed for cell growth and replication; liquid cell culture media and complementary supplements that promote cellular proliferation; and various molecular biology reagents used for the handling, rehydration, and purification of samples. Teknova caters to a diverse clientele within the life sciences arena, including pharmaceutical companies, biotechnology firms, contract development and manufacturing organizations (CDMOs), in vitro diagnostic businesses, and academic and governmental research facilities. Founded in 1996, Alpha Teknova's main office is situated in Hollister, California.

Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
Headquarters
US
CEO
Stephen Gunstream
Listed since
Jun 25, 2021
Employees
158

Market position

Day range

Current $7.36

52-week range

Current $7.36

Open
$7.14
Previous close
$7.00
Volume
220.46K
1.19× average
Average volume
186.02K
Average daily volume
Market cap
394.6M USD
Beta
0.68
Market reference 1
50-day average
$5.6518
+30.22% above average
200-day average
$4.0819
+80.31% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
212.47M USD
P/E (TTM)
-23.37×
P/B (TTM)
6.31×
P/S (TTM)
9.03×
EV / EBITDA
-20.94×
Earnings yield
-8.49%
Free cash flow yield
-4.82%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
33.94%
Operating margin
-36.19%
Net margin
-38.37%
Return on equity
-25.09%
Return on assets
-16.66%
Return on invested capital
-17.34%

Financial health

Debt / equity
0.44×
Current ratio
4.58×
Altman Z-score
5.23
Piotroski F-score
3 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends65%-3%-70%-137%Gross margin, FY2021: 47.76%Gross margin, FY2022: 42.19%Gross margin, FY2023: 28.07%Gross margin, FY2024: 19.16%Gross margin, FY2025: 33.17%Operating margin, FY2021: -32.55%Operating margin, FY2022: -119.89%Operating margin, FY2023: -96.94%Operating margin, FY2024: -69.27%Operating margin, FY2025: -41.90%Net margin, FY2021: -26.57%Net margin, FY2022: -114.60%Net margin, FY2023: -100.26%Net margin, FY2024: -70.86%Net margin, FY2025: -42.59%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 47.76%. Gross margin FY2022 42.19%. Gross margin FY2023 28.07%. Gross margin FY2024 19.16%. Gross margin FY2025 33.17%. Operating margin FY2021 -32.55%. Operating margin FY2022 -119.89%. Operating margin FY2023 -96.94%. Operating margin FY2024 -69.27%. Operating margin FY2025 -41.90%. Net margin FY2021 -26.57%. Net margin FY2022 -114.60%. Net margin FY2023 -100.26%. Net margin FY2024 -70.86%. Net margin FY2025 -42.59%.

Income trends

Revenue

40.52M USD+7.35%

Operating income

−16.98M USD+35.07%

Net income

−17.26M USD+35.47%
Income trends across reported periods50.53M USD14.1M USD−22.34M USD−58.77M USDRevenue, FY2021: 36.89M USDRevenue, FY2022: 41.42M USDRevenue, FY2023: 36.68M USDRevenue, FY2024: 37.75M USDRevenue, FY2025: 40.52M USDOperating income, FY2021: −12.01M USDOperating income, FY2022: −49.66M USDOperating income, FY2023: −35.56M USDOperating income, FY2024: −26.15M USDOperating income, FY2025: −16.98M USDNet income, FY2021: −9.8M USDNet income, FY2022: −47.47M USDNet income, FY2023: −36.78M USDNet income, FY2024: −26.75M USDNet income, FY2025: −17.26M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 36.89M USD. Revenue FY2022 41.42M USD. Revenue FY2023 36.68M USD. Revenue FY2024 37.75M USD. Revenue FY2025 40.52M USD. Operating income FY2021 −12.01M USD. Operating income FY2022 −49.66M USD. Operating income FY2023 −35.56M USD. Operating income FY2024 −26.15M USD. Operating income FY2025 −16.98M USD. Net income FY2021 −9.8M USD. Net income FY2022 −47.47M USD. Net income FY2023 −36.78M USD. Net income FY2024 −26.75M USD. Net income FY2025 −17.26M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue40.52M USD37.75M USD36.68M USD41.42M USD36.89M USD
Cost of goods sold27.08M USD30.51M USD26.39M USD23.94M USD19.27M USD
Gross profit13.44M USD7.23M USD10.3M USD17.48M USD17.62M USD
Research and development2.2M USD2.76M USD5.57M USD7.74M USD4.31M USD
Selling, general, and administrative27.07M USD29.47M USD34.78M USD37.45M USD24.17M USD
Operating expenses30.42M USD33.38M USD45.86M USD67.14M USD29.63M USD
Interest income———213K USD—
Interest expense710K USD687K USD833K USD—589K USD
Depreciation and amortization6.34M USD6.58M USD5.66M USD3.17M USD2.88M USD
Operating income−16.98M USD−26.15M USD−35.56M USD−49.66M USD−12.01M USD
Net income−17.26M USD−26.75M USD−36.78M USD−47.47M USD−9.8M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
82%
9 beats, 1 miss, 1 met estimate
Average EPS surprise
+10.66%
11 comparable reports
Latest EPS result
-0.06
Estimate -0.08 · Beat by 28.82%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0.05-0.09-0.12-0.16Q1 '25BeatQ2 '25BeatQ3 '25BeatQ4 '25BeatQ1 '26MetQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Mar 4, 2025: actual -0.11, estimate -0.12, surprise +8.33%, Beat. Q2 2025, reported May 8, 2025: actual -0.09, estimate -0.11, surprise +18.18%, Beat. Q3 2025, reported Aug 7, 2025: actual -0.07, estimate -0.1, surprise +30.25%, Beat. Q4 2025, reported Nov 6, 2025: actual -0.08, estimate -0.094, surprise +14.75%, Beat. Q1 2026, reported Feb 26, 2026: actual -0.09, estimate -0.09, surprise 0.00%, Met estimate. Q2 2026, reported May 6, 2026: actual -0.08, estimate -0.093, surprise +13.57%, Beat. Q3 2026, reported Aug 5, 2026: actual -0.06, estimate -0.084, surprise +28.82%, Beat. Q4 2026, reported Nov 5, 2026: actual —, estimate -0.06, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates12.67M11.21M9.75M8.28MQ1 '25BeatQ2 '25MissQ3 '25BeatQ4 '25BeatQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Mar 4, 2025: actual 9.27M USD, estimate 8.77M USD, surprise +5.63%, Beat. Q2 2025, reported May 8, 2025: actual 9.8M USD, estimate 9.93M USD, surprise -1.34%, Miss. Q3 2025, reported Aug 7, 2025: actual 10.29M USD, estimate 9.9M USD, surprise +3.95%, Beat. Q4 2025, reported Nov 6, 2025: actual 10.45M USD, estimate 9.62M USD, surprise +8.68%, Beat. Q1 2026, reported Feb 26, 2026: actual 9.98M USD, estimate 9.69M USD, surprise +3.03%, Beat. Q2 2026, reported May 6, 2026: actual 11.08M USD, estimate 10.23M USD, surprise +8.32%, Beat. Q3 2026, reported Aug 5, 2026: actual 12.19M USD, estimate 10.95M USD, surprise +11.26%, Beat. Q4 2026, reported Nov 5, 2026: actual —, estimate 11.69M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Rating distribution

3 ratings

Limited analyst sample: 3 ratings. Interpret the distribution with caution.

Strong buy00%
Buy3100%
Hold00%
Sell00%
Strong sell00%

Recent analyst actions

2 institutions

TKNO news

marketbeat.com

Alpha Teknova Raises Outlook After Record Q2 Revenue at Sidoti Conference

Alpha Teknova NASDAQ: TKNO Chief Financial Officer Matt Lowell said the provider of laboratory and bioprocessing reagents is seeing renewed growth, reporting record second-quarter revenue and raising its full-year…

Read source
zacks.com

Alpha Teknova (TKNO) is a Great Momentum Stock: Should You Buy?

Does Alpha Teknova (TKNO) have what it takes to be a top stock pick for momentum investors? Let's find out.

Read source
zacks.com

Wall Street Analysts Believe Alpha Teknova (TKNO) Could Rally 35.45%: Here's is How to Trade

The mean of analysts' price targets for Alpha Teknova (TKNO) points to a 35.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising…

Read source
marketbeat.com

Alpha Teknova Q2 Earnings Call Highlights

Alpha Teknova NASDAQ: TKNO reported second-quarter revenue growth of 18% from a year earlier, surpassing $12 million for its highest quarterly revenue in the company's 30-year history. The company raised its full-year…

Read source
seekingalpha.com

Alpha Teknova, Inc. (TKNO) Q2 2026 Earnings Call Transcript

Alpha Teknova, Inc. (TKNO) Q2 2026 Earnings Call Transcript

Read source
globenewswire.com

Teknova Reports Second Quarter 2026 Financial Results

Second quarter 2026 total revenue was $12.2 million, up 18% over the same quarter prior year Company raises 2026 revenue guidance to $45-47 million Launched proprietary AI-powered Build-Tek™ custom order configurator,…

Read source

TKNO peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding TKNO

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
7.39M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
iShares Russell 2000 ETF logoiShares Russell 2000 ETFIWM
Market value
2.11M
Weight
0.00%
AUM
81.62B USD
Expense ratio
0.19%
Price / 1D
$299.96+0.77%
iShares Russell 2000 Growth ETF logoiShares Russell 2000 Growth ETFIWO
Market value
673.81K
Weight
0.00%
AUM
15.16B USD
Expense ratio
0.24%
Price / 1D
$387.37+1.24%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
608.55K
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
iShares Biotechnology ETF logoiShares Biotechnology ETFIBB
Market value
568.51K
Weight
0.01%
AUM
10.75B USD
Expense ratio
0.44%
Price / 1D
$213.56+1.29%
iShares Russell 2000 Value ETF logoiShares Russell 2000 Value ETFIWN
Market value
554.43K
Weight
0.00%
AUM
14.66B USD
Expense ratio
0.24%
Price / 1D
$224.81+0.45%
Vanguard Russell 2000 ETF logoVanguard Russell 2000 ETFVTWO
Market value
319.88K
Weight
0.00%
AUM
17.4B USD
Expense ratio
0.06%
Price / 1D
$121.25+0.74%
iShares Micro-Cap ETF logoiShares Micro-Cap ETFIWC
Market value
267.6K
Weight
0.02%
AUM
1.53B USD
Expense ratio
0.60%
Price / 1D
$198.39+1.10%

Continue in GoAI

Research TKNO

research.disclaimer